| 1. |
- Prusti, T., et al.
(författare)
-
The Gaia mission
- 2016
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 595
-
Tidskriftsartikel (refereegranskat)abstract
- Gaia is a cornerstone mission in the science programme of the European Space Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page.
|
|
| 2. |
|
|
| 3. |
- Wild, CP, et al.
(författare)
-
Cancer Prevention Europe
- 2019
-
Ingår i: Molecular oncology. - : Wiley. - 1878-0261 .- 1574-7891. ; 13:3, s. 528-534
-
Tidskriftsartikel (refereegranskat)
|
|
| 4. |
- Buzolin, C. N., et al.
(författare)
-
In situ determination of dissolution kinetics of d-limonene in supercritical carbon dioxide by Raman spectroscopy
- 2017
-
Ingår i: New Journal of Chemistry. - : Royal Society of Chemistry (RSC). - 1144-0546 .- 1369-9261. ; 41:22, s. 13929-13934
-
Tidskriftsartikel (refereegranskat)abstract
- The study of solvation in pressurized systems requires in situ analysis. An optimal spectroscopic technique for such studies would enable the detection of any compound and have resolution enough to differentiate different compounds within a multicomponent mixture. Here we show for the first time that we can follow dissolution kinetics of a model compound, d-limonene, in supercritical carbon dioxide using in situ Raman spectroscopy. Dissolution rate constants were measured at different stirring speeds, temperatures (45 and 55 °C) and amounts of CO2, corresponding to pressures in the range of 8.4 to 17.0 MPa. Dissolution half-lives ranged from 3 min (at 45 °C and 8.4 MPa) up to more than 1 hour (at 55 °C 16.9 MPa). The results indicate that dissolution is mostly controlled by diffusion, while convection did not play a significant role. Dissolution rate constants showed a non-linear inverse relation with diffusivity, while temperature did not influence the dissolution rate constants significantly. Dissolution kinetics is revealed as a significant aspect to consider for the optimization of extraction and separation processes based on supercritical carbon dioxide. Overall, this study offers new insight into solvation phenomena in pressurized fluids.
|
|
| 5. |
- Smith, Matthew R, et al.
(författare)
-
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
- 2018
-
Ingår i: The New England journal of medicine. - 1533-4406. ; 378:15, s. 1408-1418
-
Tidskriftsartikel (refereegranskat)abstract
- Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death.A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).
|
|
